Literature DB >> 20364113

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.

Patrizia Sini1, Dominic James, Christine Chresta, Sylvie Guichard.   

Abstract

mTOR is a major biological switch, coordinating an adequate response to changes in energy uptake (amino acids, glucose), growth signals (hormones, growth factors) and environmental stress. mTOR kinase is highly conserved through evolution from yeast to man and in both cases, controls autophagy and cellular translation in response to nutrient stress. mTOR kinase is the catalytic component of two distinct multiprotein complexes called mTORC1 and mTORC2. In addition to mTOR, mTORC1 contains Raptor, mLST8 and PRAS40. mTORC2 contains mTOR, Rictor, mSIN1 and Protor-1. mTORC1 activates p70S6K, which in turn phosphorylates the ribosomal protein S6 and 4E-BP1, both involved in protein translation. mTORC2 activates AKT directly by phosphorylating Serine 473. pAKT(S473) phosphorylates TSC2 (tuberin) and inactivates it, preventing its association with TSC1 (hamartin) and the inhibition of Rheb, an activator of mTOR. pAKT also phosphorylates PRAS40, releasing it from the mTORC1 complex, increasing its kinase activity. Finally, AKT regulates FOXO3 phosphorylation, sequestering it in the cytosol in an inactive state.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20364113     DOI: 10.4161/auto.6.4.11671

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  33 in total

1.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Authors:  Vanessa S Rodrik-Outmezguine; Sarat Chandarlapaty; Nen C Pagano; Poulikos I Poulikakos; Maurizio Scaltriti; Elizabeth Moskatel; José Baselga; Sylvie Guichard; Neal Rosen
Journal:  Cancer Discov       Date:  2011-06-17       Impact factor: 39.397

2.  Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA.

Authors:  Le Xuan Truong Nguyen; Beverly S Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

Review 3.  Rapamycin passes the torch: a new generation of mTOR inhibitors.

Authors:  Don Benjamin; Marco Colombi; Christoph Moroni; Michael N Hall
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

4.  Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.

Authors:  M Danielle Bareford; Margaret A Park; Adly Yacoub; Hossein A Hamed; Yong Tang; Nichola Cruickshanks; Patrick Eulitt; Nisan Hubbard; Gary Tye; Matthew E Burow; Paul B Fisher; Richard G Moran; Kenneth P Nephew; Steven Grant; Paul Dent
Journal:  Cancer Res       Date:  2011-05-27       Impact factor: 12.701

Review 5.  The role of microRNA in the resistance to treatment of hepatocellular carcinoma.

Authors:  Muhammad Yogi Pratama; Devis Pascut; Muhammad Nasrum Massi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2019-10

Review 6.  Mammalian target of rapamycin (mTOR): a central regulator of male fertility?

Authors:  Tito T Jesus; Pedro F Oliveira; Mário Sousa; C Yan Cheng; Marco G Alves
Journal:  Crit Rev Biochem Mol Biol       Date:  2017-01-26       Impact factor: 8.250

7.  mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Authors:  Qun Jiang; Jonathan M Weiss; Timothy Back; Tim Chan; John R Ortaldo; Sylvie Guichard; Robert H Wiltrout
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

Review 8.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.

Authors:  Hajime Asahina; Hiroshi Nokihara; Noboru Yamamoto; Yasuhide Yamada; Yosuke Tamura; Kazunori Honda; Yoshitaka Seki; Yuko Tanabe; Hitoshi Shimada; Xiaojin Shi; Tomohide Tamura
Journal:  Invest New Drugs       Date:  2012-07-28       Impact factor: 3.850

Review 10.  mTOR-dependent cell survival mechanisms.

Authors:  Chien-Min Hung; Luisa Garcia-Haro; Cynthia A Sparks; David A Guertin
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-12-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.